CA3036071A1 - Solvate form of (r)-2-amino-3-phenylpropyl carbamate - Google Patents
Solvate form of (r)-2-amino-3-phenylpropyl carbamate Download PDFInfo
- Publication number
- CA3036071A1 CA3036071A1 CA3036071A CA3036071A CA3036071A1 CA 3036071 A1 CA3036071 A1 CA 3036071A1 CA 3036071 A CA3036071 A CA 3036071A CA 3036071 A CA3036071 A CA 3036071A CA 3036071 A1 CA3036071 A1 CA 3036071A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- amino
- apc
- carbamate hydrochloride
- phenylpropyl carbamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/08—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383822P | 2016-09-06 | 2016-09-06 | |
| US62/383,822 | 2016-09-06 | ||
| PCT/US2017/050233 WO2018048871A1 (en) | 2016-09-06 | 2017-09-06 | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3036071A1 true CA3036071A1 (en) | 2018-03-15 |
Family
ID=61562003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3036071A Abandoned CA3036071A1 (en) | 2016-09-06 | 2017-09-06 | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10829443B2 (https=) |
| EP (2) | EP3509582B1 (https=) |
| JP (3) | JP7219213B2 (https=) |
| KR (1) | KR102513800B1 (https=) |
| CN (4) | CN109996540A (https=) |
| CA (1) | CA3036071A1 (https=) |
| DK (1) | DK3509582T3 (https=) |
| ES (1) | ES2970887T3 (https=) |
| FI (1) | FI3509582T3 (https=) |
| MY (1) | MY197630A (https=) |
| PH (1) | PH12019500493A1 (https=) |
| SG (1) | SG11201901998WA (https=) |
| WO (1) | WO2018048871A1 (https=) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY197630A (en) | 2016-09-06 | 2023-06-29 | Sk Biopharmaceuticals Co Ltd | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| WO2020035769A1 (en) | 2018-08-14 | 2020-02-20 | Glenmark Pharmaceuticals Limited; Glenmark Life Sciences Limited | Process for the preparation of solriamfetol and salt thereof |
| WO2021001457A1 (en) | 2019-07-04 | 2021-01-07 | Sandoz Ag | Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts |
| IT202000013855A1 (it) | 2020-06-10 | 2021-12-10 | Flamma Spa | Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato |
| AU2023375326A1 (en) * | 2022-11-07 | 2025-05-22 | Axsome Therapeutics | Compositions and methods for treating insomnia |
| WO2024145545A2 (en) * | 2022-12-30 | 2024-07-04 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| WO2024194718A1 (en) | 2023-03-22 | 2024-09-26 | Unichem Laboratories Limited | A stable pharmaceutical composition and process for preparing thereof |
| CN121816178A (zh) | 2023-05-30 | 2026-04-07 | 艾克萨姆治疗股份有限公司 | 用于治疗患有与阻塞性睡眠呼吸暂停和白天过度嗜睡相关的认知受损的受试者的认知受损的索安非托 |
| KR20260033050A (ko) | 2023-06-29 | 2026-03-10 | 액섬 테라퓨틱스, 인크. | 수유 여성에게 솔리암페톨을 투여하는 방법 |
| WO2025042959A1 (en) | 2023-08-21 | 2025-02-27 | Axsome Therapeutics, Inc. | Use of solriamfetol for the treatment of orphan diseases |
| WO2025165760A1 (en) * | 2024-01-29 | 2025-08-07 | Axsome Therapeutics, Inc. | Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100197892B1 (ko) * | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| DK1140061T3 (da) | 1998-12-23 | 2003-08-25 | Orphan Medical Inc | Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi |
| RU2202607C2 (ru) | 2000-03-03 | 2003-04-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" | Штамм бактерий methylophilus methylotrophus - продуцент l-фенилаланина (варианты), способ получения l-фенилаланина |
| US20050080268A1 (en) * | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| RU2007119648A (ru) | 2004-10-28 | 2008-12-10 | СК Холдингз Ко. | Способ лечения депрессии |
| EP1890684B1 (en) * | 2005-06-08 | 2013-08-14 | SK Biopharmaceuticals Co., Ltd. | Treatment of sleep-wake disorders |
| ES2344469T3 (es) * | 2005-06-22 | 2010-08-27 | Sk Holdings Co., Ltd. | Tratamiento de disfuncion sexual. |
| KR20120098578A (ko) | 2009-06-22 | 2012-09-05 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| BR112012010670A2 (pt) | 2009-11-06 | 2016-04-12 | Sk Biopharmaceuticals Co Ltd | métodos para tratamento de distúrbio de défict de atenção/hiperatividade |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| CA2905457A1 (en) | 2013-03-13 | 2014-10-09 | Aerial Biopharma, Llc | Treatment of cataplexy |
| JP2016530240A (ja) | 2013-07-12 | 2016-09-29 | ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ | 禁煙の促進 |
| CA2917702A1 (en) | 2013-07-18 | 2015-01-22 | Jazz Pharmaceuticals International Iii Limited | Treatment for obesity |
| TWI698415B (zh) | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| JP2019512009A (ja) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| MY197630A (en) * | 2016-09-06 | 2023-06-29 | Sk Biopharmaceuticals Co Ltd | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| KR101950254B1 (ko) | 2016-09-21 | 2019-02-20 | 유상신 | 차량탑승자의 부재를 감지하는 지능형 카시트 |
| WO2020035769A1 (en) * | 2018-08-14 | 2020-02-20 | Glenmark Pharmaceuticals Limited; Glenmark Life Sciences Limited | Process for the preparation of solriamfetol and salt thereof |
-
2017
- 2017-09-06 MY MYPI2019001180A patent/MY197630A/en unknown
- 2017-09-06 CN CN201780065192.6A patent/CN109996540A/zh active Pending
- 2017-09-06 EP EP17849432.4A patent/EP3509582B1/en active Active
- 2017-09-06 US US16/331,069 patent/US10829443B2/en active Active
- 2017-09-06 ES ES17849432T patent/ES2970887T3/es active Active
- 2017-09-06 CN CN202511369602.9A patent/CN121202730A/zh active Pending
- 2017-09-06 SG SG11201901998WA patent/SG11201901998WA/en unknown
- 2017-09-06 DK DK17849432.4T patent/DK3509582T3/da active
- 2017-09-06 WO PCT/US2017/050233 patent/WO2018048871A1/en not_active Ceased
- 2017-09-06 FI FIEP17849432.4T patent/FI3509582T3/fi active
- 2017-09-06 CN CN202511369712.5A patent/CN121202731A/zh active Pending
- 2017-09-06 JP JP2019512895A patent/JP7219213B2/ja active Active
- 2017-09-06 CA CA3036071A patent/CA3036071A1/en not_active Abandoned
- 2017-09-06 CN CN202510706413.XA patent/CN120574152A/zh active Pending
- 2017-09-06 KR KR1020197011279A patent/KR102513800B1/ko active Active
- 2017-09-06 EP EP23218015.8A patent/EP4364794A3/en active Pending
-
2019
- 2019-03-06 PH PH12019500493A patent/PH12019500493A1/en unknown
-
2020
- 2020-11-06 US US17/091,222 patent/US11560354B2/en active Active
-
2021
- 2021-09-24 JP JP2021155292A patent/JP7642506B2/ja active Active
-
2022
- 2022-12-14 US US18/066,000 patent/US12384743B2/en active Active
-
2024
- 2024-09-19 JP JP2024161956A patent/JP2024178291A/ja active Pending
-
2025
- 2025-07-11 US US19/266,767 patent/US20250340509A1/en active Pending
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12128021B1 (en) | 2016-07-22 | 2024-10-29 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263151B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097176B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097175B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12109186B2 (en) | 2016-07-22 | 2024-10-08 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115142B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115144B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115143B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115145B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12239625B2 (en) | 2016-07-22 | 2025-03-04 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12138239B2 (en) | 2016-07-22 | 2024-11-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12144793B2 (en) | 2016-07-22 | 2024-11-19 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263150B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12257223B2 (en) | 2016-07-22 | 2025-03-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186298B2 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226389B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226388B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics |
| US12226377B2 (en) | 2019-03-01 | 2025-02-18 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167992B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167991B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12303478B2 (en) | 2019-03-01 | 2025-05-20 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12295926B1 (en) | 2022-02-07 | 2025-05-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US12551457B1 (en) | 2022-02-07 | 2026-02-17 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Also Published As
| Publication number | Publication date |
|---|---|
| CN120574152A (zh) | 2025-09-02 |
| SG11201901998WA (en) | 2019-04-29 |
| JP7219213B2 (ja) | 2023-02-07 |
| EP3509582A1 (en) | 2019-07-17 |
| JP7642506B2 (ja) | 2025-03-10 |
| US20250340509A1 (en) | 2025-11-06 |
| EP3509582A4 (en) | 2020-05-13 |
| MY197630A (en) | 2023-06-29 |
| US12384743B2 (en) | 2025-08-12 |
| EP4364794A2 (en) | 2024-05-08 |
| US20230183172A1 (en) | 2023-06-15 |
| US10829443B2 (en) | 2020-11-10 |
| DK3509582T3 (en) | 2024-02-12 |
| WO2018048871A1 (en) | 2018-03-15 |
| FI3509582T3 (fi) | 2024-02-08 |
| KR20190065311A (ko) | 2019-06-11 |
| US20210053912A1 (en) | 2021-02-25 |
| JP2022003062A (ja) | 2022-01-11 |
| JP2024178291A (ja) | 2024-12-24 |
| CN121202730A (zh) | 2025-12-26 |
| US20190194126A1 (en) | 2019-06-27 |
| CN109996540A (zh) | 2019-07-09 |
| EP4364794A3 (en) | 2024-07-24 |
| CN121202731A (zh) | 2025-12-26 |
| JP2019535643A (ja) | 2019-12-12 |
| EP3509582B1 (en) | 2023-12-20 |
| PH12019500493A1 (en) | 2019-05-27 |
| ES2970887T3 (es) | 2024-05-31 |
| US11560354B2 (en) | 2023-01-24 |
| KR102513800B1 (ko) | 2023-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12384743B2 (en) | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof | |
| AU2018312328B2 (en) | Carbamoyl phenylalaninol analogs and uses thereof | |
| EP1485388A2 (en) | Topiramate salts and compositions comprising and methods of making and using the same | |
| KR20140111044A (ko) | 구연산아일데나필 결정 형태 o 및 그의 제조방법과 용도 | |
| ES2587064T3 (es) | Sales fumarato novedosas de un antagonista del receptor de histamina H3 | |
| WO2004067496A9 (en) | Crystalline form of nateglinide | |
| KR102509190B1 (ko) | 트리메부틴 말레산염의 다형체 및 이의 사용방법 | |
| CN118647618A (zh) | Rabeximod化合物 | |
| HK40009279A (en) | Solvate form of (r)-2-amino-3-phenylpropyl carbamate | |
| JPH02237928A (ja) | 置換ベンズアミドより成る胃の自動運動性増進用薬剤 | |
| US6544977B1 (en) | Crystalline forms of 1s-[1-alpha(2s*,3r*), 9alpha]6, 10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9[[(1-isoquinolyl)carbonyl]amino]octahydro-6h-pyridazino [1,2-a] [1,2] diazepin-1-carboxamide | |
| WO2025170483A1 (ru) | Фармацевтическая композиция, обладающая антибиотической активностью | |
| EA050094B1 (ru) | Синтез (2s,5r)-5-(2-хлорфенил)-1-(2'-метокси-[1,1'-бифенил]-4-карбонил)пирролидин-2-карбоновой кислоты | |
| HK40028824A (en) | Polymorphic forms of trimebutine maleate and method of using same | |
| CN109535149A (zh) | 甲磺酸替扎尼定化合物及其制备方法和用途 | |
| EA041334B1 (ru) | Новые полиморфные формы тримебутина малеата, способ получения и применения | |
| EA044497B1 (ru) | Новые полиморфные формы тримебутина малеата, способ получения и применения | |
| JPS63152359A (ja) | ２−置換−〔２−置換−アミノ〕−ｎ−アリールアルキル−３−〔インドール−３−イル〕プロパンアミド | |
| CN109535151A (zh) | 对甲苯磺酸替扎尼定晶型a及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20231219 |